ProfileGDS5678 / 1419508_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 71% 69% 69% 70% 71% 66% 69% 69% 69% 72% 70% 69% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.4018570
GSM967853U87-EV human glioblastoma xenograft - Control 24.5177171
GSM967854U87-EV human glioblastoma xenograft - Control 34.2715869
GSM967855U87-EV human glioblastoma xenograft - Control 44.3385669
GSM967856U87-EV human glioblastoma xenograft - Control 54.3811670
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.4699771
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0429166
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2474569
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2639869
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.2902869
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.5860272
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.4322170
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.2454369
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3997571